A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy



Status:Active, not recruiting
Conditions:Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/17/2019
Start Date:January 27, 2009
End Date:October 27, 2020

Use our guide to learn which trials are right for you!

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial)

The purpose of this study is to determine if lenalidomide (Revlimid®) is safe and effective
as a maintenance therapy at improving further the quality of the response you achieved with
your last therapy and at prolonging the duration of your response. This study will compare
the effects (good and bad) of lenalidomide with the dummy drug.

This is a phase 3, randomized (computer assigned by chance to treatment arm), study being
completed an multiple sites to compare the safety and efficacy (how well a drug works) of
lenalidomide maintenance therapy to placebo (dummy capsule that contains no lenalidomide or
active substances) maintenance therapy.

Patients are assigned by a computer with a 50/50 chance to receive placebo or lenalidomide
study treatment. Study drug will be taken once each day until the patient discontinues the
study. Patients will remain on study drug until progression of disease.

Patients will visit their study doctor every 28 days until disease progression to complete
safety and efficacy assessments. Quality of life assessments will be completed every other
month. If a patient who discontinue study drug prior to disease progression (i.e. due to an
adverse reaction to the study drug), they will continue to visit the study doctor each month
to complete the efficacy assessments up to progression of disease. Safety assessments may
include laboratory blood tests, ECG tests and questions about any medical conditions or side
effects experienced during the study. Efficacy assessments may include laboratory blood tests
and focused physical exams.

Computed tomography (CT) scans along with blood tests and bone marrow samples will be
collected to confirm if a patient has improvement of response while on study.

After disease progression, patients will be contacted every 12 weeks for survival
information, next CLL treatments and quality of life questions.

Subjects currently on lenalidomide treatment will discontinue lenalidomide treatment
immediately and complete the Treatment Discontinuation assessment. The subjects will then
transition to the survival follow-up period.

Inclusion Criteria:

1. Must understand and voluntarily sign an informed consent form.

2. Must be greater than or equal to 18 years at the time of signing the informed consent
form.

3. Must be able to adhere to the study visit schedule and other protocol requirements.

4. Must have a documented diagnosis of B-cell CLL (IWCLL guidelines for the diagnosis and
treatment of chronic lymphocytic leukemia [Hallek, 2008]).

5. Must have been treated with one of the following in first and/or second line:

- a purine analog-containing regimen

- a bendamustine-containing regimen

- an anti-CD20 antibody-containing regimen

- a chlorambucil-containing regimen

- an alemtuzumab-containing regimen (for those subjects with a 17p deletion)

6. Must have achieved a minimum response of partial response (PR, nPR, CRi, CR, and
MRD-negative CR) (IWCLL guidelines for the diagnosis and treatment of chronic
lymphocytic leukemia [Hallek, 2008]) following completion of second-line induction
therapy prior to randomization (documentation of response status must be available).
Second-line induction therapy must be documented to have been of sufficient duration.

7. Must have completed last cycle of second-line induction no less than 8 weeks (56 days)
and no greater than 20 weeks (140 days) prior to randomization.

8. Must have an ECOG performance status score of less than or equal to 2.

9. Females of childbearing potential (FCBP)† must:

- Have two negative medically supervised pregnancy tests prior to starting of study
therapy. She must agree to ongoing pregnancy testing during the course of the
study, and after end of study therapy. This applies even if the subject practices
complete and continued sexual abstinence.

- Either commit to continued abstinence from heterosexual contact (which must be
reviewed on a monthly basis) or agree to use, and be able to comply with,
effective contraception without interruption, 28 days prior to starting study
drug, during the study therapy (including dose interruptions), and for 28 days
after discontinuation of study therapy.

10. Male subjects must:

- Commit to continued abstinence from heterosexual contact or agree to use a condom
during sexual contact with a FCBP, even if they have had a vasectomy, throughout
study drug therapy, during any dose interruption and after cessation of study
therapy.

- Agree to not donate semen during study drug therapy and for a period after end of
study drug therapy.

11. All subjects must:

- Have an understanding that the study drug could have a potential teratogenic
risk.

- Agree to abstain from donating blood while taking study drug therapy and
following discontinuation of study drug therapy. • Agree not to share study
medication with another person.

- All subjects must be counseled about pregnancy precautions and risks of fetal
exposure.

Exclusion Criteria:

1. Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from participating in the study.

2. Active infections requiring systemic antibiotics.

3. Systemic infection that has not resolved > 2 months prior to initiating lenalidomide
treatment in spite of adequate anti-infective therapy

4. Autologous or allogeneic bone marrow transplant as second-line therapy.

5. Pregnant or lactating females.

6. Systemic treatment for B-cell CLL in the interval between completing the last cycle of
second-line induction therapy and randomization.

7. Participation in any clinical study or having taken any investigational therapy for a
disease other than CLL within 28 days prior to initiating maintenance therapy.

8. Known presence of alcohol and/or drug abuse.

9. Central nervous system involvement as documented by spinal fluid cytology or imaging.
Subjects who have signs or symptoms suggestive of leukemic meningitis or a history of
leukemic meningitis must have a lumbar puncture procedure performed within two weeks
prior to randomization.

10. Prior history of malignancies, other than CLL, unless the subject has been free of the
disease for ≥5 years. Exceptions include the following:

- Basal cell carcinoma of the skin

- Squamous cell carcinoma of the skin

- Carcinoma in situ of the cervix

- Carcinoma in situ of the breast

- Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)

11. History of renal failure requiring dialysis.

12. Known Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV), and/or
active Hepatitis C Virus (HCV) infection.

13. Prior therapy with lenalidomide.

14. Evidence of TLS per the Cairo-Bishop definition of laboratory TLS (subjects may be
enrolled upon correction of electrolyte abnormalities).

15. Any of the following laboratory abnormalities:

- Calculated (method of Cockroft-Gault) creatinine clearance <60 mL/min.

- Absolute neutrophil count (ANC) <1,000/μL (1.0 X 109/L)

- Platelet count <50,000/μL (50 X 109/L)

- Serum aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase
(SGOT) or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT)
> 3.0 x upper limit of normal (ULN)

- Serum total bilirubin >2.0 mg/dL (with the exception of Gilbert's Syndrome)

16. Grade 4 rash due to prior thalidomide treatment

17. Uncontrolled hyperthyroidism or hypothyroidism

18. Venous thromboembolism within one year

19. Greater than or equal to Grade-2 neuropathy

20. Uncontrolled autoimmune hemolytic anemia or thrombocytopenia

21. Disease transformation (active) (ie, Richter's Syndrome, prolymphocytic leukemia)

22. Known allergy to allopurinol for subjects assessed with PR following their second-line
induction therapy.

23. Prisoners.

24. More than 2 prior lines of CLL therapy.
We found this trial at
57
sites
800 8th Street
Boca Raton, Florida 33486
?
mi
from
Boca Raton, FL
Click here to add this to my saved trials
14529 Cortez Boulevard
Brooksville, Florida 34613
?
mi
from
Brooksville, FL
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
4000 Waterman Way
Tavares, Florida 32778
?
mi
from
Tavares, FL
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
Ames, Iowa 50010
McFarland Clinic, PC It has been over 65 years since the founders of McFarland Clinic...
?
mi
from
Ames, IA
Click here to add this to my saved trials
Augusta, Georgia 30901
?
mi
from
Augusta, GA
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Canton, OH
Click here to add this to my saved trials
Charleston, South Carolina 29403
?
mi
from
Charleston, SC
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
5053 Wooster Rd
Cincinnati, Ohio 45226
(513) 751-2273
Oncology Hematology Care Our more than 60 physicians and advanced practice providers throughout neighborhood offices...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
2139 Auburn Ave
Cincinnati, Ohio 45219
(513) 585-2000
The Christ Hospital For more than 120 years, The Christ Hospital has been a leader...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Concord, New South Wales 2138
?
mi
from
Concord,
Click here to add this to my saved trials
2201 Inwood Rd
Dallas, Texas 75235
(214) 645-8300
U.T. Southwestern Medical Center The story of UT Southwestern Medical Center is one of commitment...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denver, Colorado 80218
?
mi
from
Denver, CO
Click here to add this to my saved trials
Dover, Ohio 44622
?
mi
from
Dover, OH
Click here to add this to my saved trials
Fountain Valley, California 92708
?
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Gettysburg, Pennsylvania 17325
?
mi
from
Gettysburg, PA
Click here to add this to my saved trials
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
1 Ingalls Dr
Harvey, Illinois 60426
(708) 333-2300
Ingalls Memorial Hospital As the area's only independent not-for-profit healthcare system, Ingalls has the ability...
?
mi
from
Harvey, IL
Click here to add this to my saved trials
Hines, Illinois 60141
?
mi
from
Hines, IL
Click here to add this to my saved trials
Hollywood, Florida 33021
?
mi
from
Hollywood, FL
Click here to add this to my saved trials
Jacksonville, Florida 32216
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
La Crosse, Wisconsin 54601
?
mi
from
La Crosse, WI
Click here to add this to my saved trials
Las Vegas, Nevada 89106
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
?
mi
from
Marietta, GA
Click here to add this to my saved trials
259 1st St
Mineola, New York 11501
(516) 663-0333
Winthrop University Hospital Founded in 1896 by a group of local physicians and concerned citizens,...
?
mi
from
Mineola, NY
Click here to add this to my saved trials
230 25th Ave N
Nashville, Tennessee 37203
(615) 329-7274
Sarah Cannon Cancer Center People who live with cancer
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
New Albany, IN
Click here to add this to my saved trials
New Hyde Park, New York 11042
?
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
New Orleans, Louisiana 70121
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
North Chicago, Illinois 60064
?
mi
from
North Chicago, IL
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phoenix, Arizona 85054
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
4800 Friendship Ave
Pittsburgh, Pennsylvania 15224
(412) 578-5000
Western Pennsylvania Hospital Featuring 308 private patient beds, West Penn Hospital has served Bloomfield and...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Plainville, Connecticut
?
mi
from
Plainville, CT
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
San Diego, California 92120
?
mi
from
San Diego, CA
Click here to add this to my saved trials
7901 Frost Street
San Diego, California 92123
858-939-3400
Sharp Memorial Hospital Sharp Memorial Hospital offers clinical excellence with the latest technology and patient-centered...
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Seattle, Washington 98104
?
mi
from
Seattle, WA
Click here to add this to my saved trials
230 Nebraska St.
Sioux City, Iowa 51101
712-252-0088
Siouxland Hematology-Oncology Associates, LLP Siouxland Hematology-Oncology Associates (SHOA) provides medical oncology treatment. In addition to...
?
mi
from
Sioux City, IA
Click here to add this to my saved trials
?
mi
from
Skokie, IL
Click here to add this to my saved trials
Stanford, California 94305
?
mi
from
Stanford, CA
Click here to add this to my saved trials
Sumter, South Carolina 29150
?
mi
from
Sumter, SC
Click here to add this to my saved trials
?
mi
from
Syracuse, NY
Click here to add this to my saved trials
Tavares, Florida 32778
?
mi
from
Tavares, FL
Click here to add this to my saved trials
Valhalla, New York 10595
?
mi
from
Valhalla, NY
Click here to add this to my saved trials
Wenatchee, Washington 98801
?
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Willow Grove, Pennsylvania 19090
?
mi
from
Willow Grove, PA
Click here to add this to my saved trials
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Wooster, Ohio 44691
?
mi
from
Wooster, OH
Click here to add this to my saved trials